Trials / Terminated
TerminatedNCT06388759
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
A Phase Ib Study of TQ05105 Tablets for the Treatment of Intermediate and High Risk Myelofibrosis Refractory/Relapsed/Intolerant to Ruxolitinib
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy of TQ05105 Tablets in patients with intermediate-risk and high-risk myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 Tablets | TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2025-08-12
- Completion
- 2025-08-12
- First posted
- 2024-04-29
- Last updated
- 2025-08-29
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06388759. Inclusion in this directory is not an endorsement.